SQZ Biotechnologies (OTCMKTS:SQZB – Get Free Report) is expected to issue its resultson Thursday, March 26th. Analysts expect the company to announce earnings of ($0.5725) per share and revenue of $5.79 million for the quarter.
SQZ Biotechnologies Stock Performance
SQZB stock remained flat at $0.02 during trading on Wednesday. SQZ Biotechnologies has a 1-year low of $0.02 and a 1-year high of $0.05. The company’s fifty day moving average is $0.02 and its two-hundred day moving average is $0.02.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies (OTCMKTS:SQZB) is a clinical-stage biotechnology company focused on developing novel cell therapies through its proprietary microfluidic delivery technology. The company’s core “Cell Squeeze” platform temporarily disrupts cell membranes to enable direct intracellular delivery of a wide range of biomolecules, including proteins, peptides and nucleic acids, without relying on viral vectors. This approach is designed to improve manufacturing efficiency, enhance safety profiles and broaden the applicability of cell-based therapies across multiple disease areas.
The company’s pipeline spans oncology, infectious disease and regenerative medicine.
See Also
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
